Evidence map›Paper›PMID 32398721›Full record

ArticleMolecular psychiatry2021

White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naïve first-episode psychosis patients.

Nina Vanessa Kraguljac, Thomas Anthony, Charity Johanna Morgan, Ripu Daman Jindal, Mark Steven Burger, Adrienne Carol Lahti

Abstract read
In one paragraph

Article in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nina Vanessa KraguljacDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA. nkraguljac@uabmc.edu.ORCID http://orcid.org/0000-0003-2567-4098
Thomas AnthonyDepartment of Electrical and Computer Engineering/ IT Research Computing, University of Alabama at Birmingham, Birmingham, AL, USA.
Charity Johanna MorganDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA.
Ripu Daman JindalDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Mark Steven BurgerDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Adrienne Carol LahtiDepartment of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

Trajectories of treatment response as window into the heterogeneity of psychosis: a longitudinal multimodal imaging study in medication-naieve first episode psychosis patientsR01MH113800 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2018 to 2022
$3.9M
Contribution of Glutamate Excess and Inflammation to Progressive White Matter Changes in PsychosisR01MH118484 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRAGULJAC, NINA VANESSA · 2019 to 2023
$3.3M
Glutamate, brain connectivity and duration of untreated psychosisR01MH102951 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAHTI, ADRIENNE C · 2014 to 2018
$2.9M
Glutamate reducing interventions in schizophreniaR61MH112800 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SMALL, SCOTT A · 2017 to 2018
$1.4M
Structural and Neurometabolic White Matter Integrity in the Deficit SyndromeK23MH106683 · NIMH · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KRAGULJAC, NINA VANESSA · 2015 to 2019
$883k
NIMH NIH HHS K23 MH106683NIMH NIH HHS R01 MH102951NIMH NIH HHS R01 MH113800NIMH NIH HHS R01 MH118484NIMH NIH HHS R61 MH112800
6 · The paper itself

Abstract

It is becoming increasingly clear that longer duration of untreated psychosis (DUP) is associated with adverse clinical outcomes in patients with psychosis spectrum disorders. Because this association is often cited when justifying early intervention efforts, it is imperative to better understand underlying biological mechanisms. We enrolled 66 antipsychotic-naïve first-episode psychosis (FEP) patients and 45 matched healthy controls in this trial. At baseline, we used a human connectome style diffusion-weighted imaging (DWI) sequence to quantify white matter integrity in both groups. Patients then received 16 weeks of treatment with risperidone, 51 FEP completed the trial. We compared whole-brain fractional anisotropy (FA), mean diffusivity, axial diffusivity (AD), and radial diffusivity between groups. To test if structural white matter integrity mediates the relationship between longer DUP and poorer treatment response, we fit a mediator model and estimated indirect effects. We found decreased whole-brain FA and AD in medication-naive FEP compared with controls. In patients, lower FA was correlated with longer DUP (r = -0.32; p = 0.03) and poorer subsequent response to antipsychotic treatment (r = 0.40; p = 0.01). Importantly, we found a significant mediation effect for FA (indirect effect: -2.70; p = 0.03), indicating that DUP exerts its effects on treatment response through affecting white matter integrity. Our data provide empirical support to the idea the DUP may have fundamental pathogenic effects on the natural history of psychosis, suggest a biological mechanism underlying this phenomenon, and underscore the importance of early intervention efforts in this disabling neuropsychiatric syndrome.

Indexed as

Antipsychotic AgentsPsychotic DisordersWhite MatterBrainHumansRisperidoneAntipsychotic AgentsRisperidone

Identifiers

PMID32398721
PMCPMC7658031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.